证券代码：A 股 600613 股票简称：A 股 神奇制药 编号： 2023-037 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 第十一届监事会第三次会议决议公告 3．公司监事会在提出审核意见前，没有发现参与公司 2023 年第三季度报告 及摘要编制和审议的人员有违反保密规定的行为。 4．全体监事保证公司 2023 年第三季度报告及摘要所披露的信息真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带责任。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 上海神奇制药投资管理股份有限公司监事会 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届监事会 第三次会议通知于 2023 年 10 月 25 日分别以传真、邮件、短信等方式通知全体 监事，会议于 2023 年 10 月 30 日以通讯表决方式召开。会议应参加表决监事 3 人，实际参加表决监事 3 人。根 ...

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2023-038 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2023 年三季度主要运营数据公告 1．主营业务分行业情况 单位：元 2．主营业务分类情况 单位：元 1 分行业 2023年1-9月营业 收入 2023 年 1-9 月营 业成本 毛利率 （%） 营业收 入比上 年同期 增减（%） 营业成 本比上 年同期 增减（%） 毛利率 比上年 同期增 减（%） 一、医药制造 1,072,789,062.61 248,702,015.41 76.82 -4.76 4.75 -2.11 二、医药商业 637,753,886.34 576,327,653.89 9.63 8.76 10.18 -1.16 合计 1,710,542,948.95 825,029,669.30 51.77 -0.13 8.49 -3.83 分产品 营业收入 营业成本 毛利率 （%） 营业收入 比上年同 期增减 （%） 营业成本 比上年同 期增减（%） 毛利率 比上年 同期增 减（%） 抗肿瘤药 系列 542,886,935.12 52,0 ...

根据《证券法》和上海证券交易所《关于做好上市公司 2023 年第三季度报 告披露工作的通知》的有关要求,我们作为公司董事、监事和高级管理人员，在 全面了解和审核公司 2023 年三季度报告后，对公司 2023 年三季度报告发表如下 书面确认意见： 上海神奇制药投资管理股份有限公司董事、监事和高级管理人员 对公司 2023 年第三季度报告的书面确认意见 | ZHANG TAO TAO | | 张芝庭 | | 冯 | 斌 | | --- | --- | --- | --- | --- | --- | | 吴 | 涛 | 徐 | 丹 | 陈之勉 | | | 独立董事： | | | | | | | 陈世贵 | | 段竞晖 | | 李丛艳 | | | 监事： | | | | | | | 夏宇波 | | 宋晓宇 | | 胡 | 岚 | | 高级管理人员： | | | | | | | 陈之勉 | | 吴克兢 | | | | 2023 年 10 月 30 日 我们一致认为：公司严格按照股份制公司财务制度规范运作，公司 2023 年 第三季度报告公允地反映了公司 2023 年第三季度的财务状况和经营成果，我们 确认公司 202 ...

审议通过《公司 2023 年第三季度报告》（全文详见上交所网站： http://www.sse.com.cn） 表决结果：同意 9 票，反对 0 票，弃权 0 票。 特此公告。 | | | 上海神奇制药投资管理股份有限公司 第十一届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）第十一届董事会 第三次会议通知已于 2023 年 10 月 25 日分别以送达、传真、邮件等方式通知公 司董事、监事。会议于 2023 年 10 月 30 日以通讯表决方式召开。会议应参加表 决董事 9 人，实际参加表决董事 9 人；会议符合《公司法》及《公司章程》的有 关规定，会议及表决合法有效。经审议，会议通过如下决议： 上海神奇制药投资管理股份有限公司董事会 2023 年 10 月 31 日 ...

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-035 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于控股股东部分股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公 司"）控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"）持有 公司 120,661,620 股，占公司总股本 22.59%；本次质押 20,800,000 股，累计质 押股份 60,300,000 股，占公司总股份数 11.29%，占其持有公司股份 49.97%。 神奇控股及其控股公司贵州迈吉斯投资管理有限公司（以下简称"迈吉 斯"）合计持有公司 208,663,566 股，占公司总股本 39.07%；累计质押股份 112,050,000 股，占公司总股份数 20.98 ...

上海神奇制药投资管理股份有限公司 关于股东股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-029 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 2、本次质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他 保障用途的情形。 3、控股股东及其控股公司累计质押股份情况 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公 司"） 的股东贵州迈吉斯投资管理有限公司（以下简称"迈吉斯"）持有公司 88,001,946 股，占公司总股本 16.48%；本次质押 10,350,000 股，累计质押股份 51,750,000 股，占公司总股份数 9.69%，占其持有公司股份 58.81%。 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"） 神奇控股及其控股公司迈吉斯合计持有 ...

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-028 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于股东部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公司"） 的股东贵州迈吉斯投资管理有限公司（以下简称"迈吉斯"）持有公司 88,001,946 股，占公司总股本 16.48%；办理了股票质押式回购交易，解除质押 18,600,000 股。本次解除质押后，迈吉斯累计质押股份 41,400,000 股，占公司 总股份数 7.75%，占其持有公司股份 47.04%。 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"） 及其控股的迈吉斯合计持有公司 208,663,566 股，占公司总股本 39.07%；累计 质押股份 80 ...

重要内容提示： ●会议召开时间： 2023 年 5 月 10 日（周三）15:00 至 17:00 ●会议召开方式：上证路演中心网络互动 ● 会议召开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 为进一步加强与广大投资者的沟通交流，上海神奇制药投资管理股份有限公 司（以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说明会" 活动，现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录"上证路演中 心"网站（http://roadshow.sseinfo.com）或关注微信公众号上证路演中心参 与活动，活动时间为 2023 年 5 月 10 日（周三）15:00 至 17:00。投资者可于 2023 年 5 月 5 日（星期五）16:00 前通过公司邮箱 shanghaiys@126.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 届时公司的董事总经理冯斌先生、独立董事陈世贵先生、财务总监李发淼先 生和董事会秘书吴克兢先生将通过网络在线交流形式与投资者就 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥510,571,558.22, a decrease of 6.73% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥23,472,714.69, an increase of 171.27% year-on-year[7]. - The net profit after deducting non-recurring gains and losses reached ¥26,566,007.86, up 229.29% from the previous year[7]. - Basic earnings per share were ¥0.04, representing a 119.75% increase year-on-year[7]. - Total operating revenue for the first three quarters of 2022 reached ¥1,712,817,975.79, a slight increase from ¥1,703,088,380.27 in the same period of 2021[20]. - Net profit for the first three quarters of 2022 was ¥56,932,916.95, up from ¥53,907,174.09 in the previous year, reflecting a growth of approximately 5.6%[21]. - The company's operating profit for the first three quarters of 2022 was ¥75,387,073.16, slightly down from ¥78,860,854.58 in 2021[21]. - The company reported a total comprehensive income of ¥43,819,934.28 for the first three quarters of 2022, down from ¥56,197,317.60 in the same period of 2021[22]. Cash Flow - Cash flow from operating activities was ¥159,891,524.42, reflecting a significant increase of 429.73% compared to the same period last year[7]. - The total cash inflow from operating activities for the first three quarters of 2022 was CNY 1,770,453,361.85, an increase from CNY 1,641,958,522.96 in the same period of 2021, representing a growth of approximately 7.85%[24]. - The net cash flow from operating activities was CNY 270,481,490.46, significantly higher than CNY 114,101,576.47 in the previous year, indicating a year-over-year increase of about 137.5%[24]. - The total cash outflow for operating activities was CNY 1,499,971,871.39, slightly down from CNY 1,527,856,946.49 in the previous year, indicating a decrease of about 1.8%[24]. - Cash inflow from financing activities totaled CNY 9,000,000.00, up from CNY 710,000.00 in the previous year, marking a substantial increase[25]. - The net cash flow from financing activities was CNY -113,198,364.85, compared to CNY -39,568,074.78 in the same period last year, indicating a worsening in financing cash flow[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,216,027,613.32, an increase of 2.13% from the end of the previous year[8]. - Total current assets as of September 30, 2022, reached ¥1,588,339,670.26, up from ¥1,445,855,256.17[16]. - Non-current assets totaled ¥1,627,687,943.06, down from ¥1,703,114,865.26 year-over-year[17]. - The total liabilities of the company as of the third quarter of 2022 amounted to ¥835,179,707.99, compared to ¥756,453,562.62 in the previous year, showing an increase of approximately 10.4%[22]. - The total equity attributable to shareholders was ¥2,333,166,388.39, a slight decrease from ¥2,344,283,894.81 in the previous year[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,737[14]. - The company has a total of 120,661,620 shares held by Guizhou Magic Investment Co., Ltd., representing 22.59% of total shares[14]. Research and Development - Research and development expenses increased by 30.39% during the reporting period[11]. - Research and development expenses increased to ¥36,536,409.04 in 2022 from ¥28,020,773.91 in 2021, representing a growth of about 30.5%[20]. Financial Expenses - The company reported a significant increase in financial expenses by 307.48% due to interest from project financing being included in financial costs[11]. - The company’s financial expenses increased to ¥9,200,529.27 in 2022 from ¥2,257,892.38 in 2021, indicating a significant rise in financial costs[20]. Accounts Receivable and Payables - Accounts receivable increased to ¥496,458,545.09 from ¥455,172,386.90 year-over-year[16]. - Other payables rose to ¥244,392,301.84 from ¥148,604,944.25 year-over-year[17]. - The company reported a significant increase in accounts receivable financing, which decreased to ¥105,686,194.12 from ¥147,701,457.06 year-over-year[16]. Cash and Cash Equivalents - Cash and cash equivalents as of September 30, 2022, amount to ¥630,833,391.19, an increase from ¥493,799,824.37 at the end of 2021[16]. - The ending balance of cash and cash equivalents was CNY 630,775,637.12, an increase from CNY 481,997,752.68 at the end of the same period last year, representing a growth of approximately 30.9%[25]. - The company received CNY 8,595,681.65 in tax refunds, compared to CNY 1,958,078.06 in the previous year, showing a significant increase[24].

Financial Performance - The company's operating revenue for 2021 was RMB 2,303,032,719, representing a 26.61% increase compared to RMB 1,819,006,691 in 2020[19]. - Net profit attributable to shareholders reached RMB 69,622,537, a significant increase of 120.41% from a loss of RMB 341,202,593 in 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 38,620,696, up 111.21% from a loss of RMB 344,510,890 in the previous year[22]. - Cash flow from operating activities increased by 85.94%, totaling RMB 184,263,469 compared to RMB 99,097,235 in 2020[19]. - Basic and diluted earnings per share were both RMB 0.13, a 120.31% increase from a loss of RMB 0.64 in 2020[20]. - The weighted average return on equity rose to 3.01%, an increase of 20.88 percentage points from -17.87% in 2020[20]. - The total assets at the end of 2021 were RMB 3,148,970,121, a 1.65% increase from RMB 3,097,971,351 at the end of 2020[19]. - The net assets attributable to shareholders increased by 2.94% to RMB 2,344,283,895 from RMB 2,277,367,601 in 2020[19]. - The company disposed of an investment subsidiary, generating an investment income of over RMB 28,100,000, contributing to the profit growth[22]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2021[4]. - The cash dividend policy is in compliance with the company's articles of association and has clear standards and ratios for distribution[200]. Risk Management - The company emphasizes that forward-looking statements regarding future plans and development strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[5]. - The company has detailed potential risks in the section discussing future development in the annual report[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[6]. - There are no violations of decision-making procedures regarding external guarantees[6]. - The company is closely monitoring industry policy changes and regulatory risks, establishing a dynamic warning mechanism to adapt to new regulations and maintain profitability[155]. Research and Development - The company continues to innovate in drug research and development, achieving multiple technological advancements and applying for national patents[36]. - Research and development expenses rose to CNY 50.95 million, reflecting a 19.06% increase from the previous year[83]. - The company holds a total of 133 patents, including 84 invention patents, enhancing its market competitiveness[80]. - The company is increasing investment in R&D for traditional Chinese medicine products, focusing on optimizing production processes and enhancing quality control standards[112]. - The company is conducting evidence-based medical research on sodium cantharidate products to explore further indications and derivative development[113]. Market Position and Strategy - The company is focusing on brand building as a systematic project to enhance its industry position and brand image[44]. - The company has a market share leading position in its core product, the sodium cantharidate series, which is a unique product in the country[68]. - The company collaborates with well-known hospitals for clinical research and technology transfer, enhancing its competitive edge in the industry[73]. - The company is actively exploring the dermatology and chronic disease segments, emphasizing the development of unique and key products to address chronic diseases and skin conditions[146]. - The company is positioned to leverage policy advantages and market demand in the pharmaceutical sector, particularly in response to the COVID-19 pandemic and related healthcare needs[110]. Corporate Governance - The company has established a robust corporate governance structure to ensure independent operations and protect shareholder rights[169]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independence[170]. - The company has established performance evaluation standards and procedures for senior management[171]. - The company has implemented a management system for information disclosure to ensure timely and accurate information sharing with shareholders[171]. - The company respects the rights of stakeholders, including creditors and employees, to promote sustainable development[171]. Operational Efficiency - The company is committed to cost control and efficiency improvement through lean management initiatives, aiming to reduce production costs and enhance operational efficiency[150]. - The company is enhancing its internal control systems to mitigate operational risks and improve efficiency, focusing on compliance and risk prevention measures[151]. - The company has implemented online operations and remote video meetings to ensure stable product quality and market supply during the pandemic[157]. - The company is enhancing procurement management and establishing strategic inventory reserves to mitigate raw material cost pressures[159]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,371, with 7 in the parent company and 1,364 in subsidiaries[194]. - The workforce includes 514 production personnel, 115 sales personnel, 221 technical personnel, 47 financial personnel, and 474 administrative personnel[194]. - The company emphasizes performance-based salary structures, linking employee compensation to company and individual performance[195]. - Future adjustments to the salary system will consider operational results and local market conditions to enhance employee benefits[196]. - The company has implemented targeted training programs to improve employee skills and overall management levels[197].